A comparison of two different systems for CD34+ selection of autologous or allogeneic PBSC collections.

This study compared CD34 selection procedures using the CellPro CEPRATE and the Baxter Isolex 300 systems. Thirty-two procedures were performed, 19 CEPRATE and 13 Isolex. Median starting CD34 percentages were (CEPRATE/Isolex) 0.80% (range 0.24%-7.73%) and 0.85% (range 0.27%-10.17%), respectively (p = 0.788). After selection, there was a highly significant difference in purity of the product (CEPRATE/Isolex), 54% and 82% respectively (p < 0.0001). There was no significant difference in median recovery (CEPRATE/Isolex), 43% and 50%, respectively (p = 0.383). The starting CD34 percentage influenced the purity of the final product, and at high and low starting percentages, the Isolex produced superior purity. Improved efficacy of T cell depletion was observed with the Isolex, a median log depletion of 3.4 compared with 2.9 for the CEPRATE system (p = 0.012). In conclusion, the Isolex 300i produced a significantly higher purity CD34+ fraction, even at starting CD34+ levels of <0.5%, with no significant difference in recovery when compared with the CEPRATE system. The associated log T cell depletion is significantly improved with the Isolex system, with possible implications for use in CD34-selected allogeneic transplants.

[1]  L. Fouillard,et al.  Preparation and successful engraftment of purified CD34+ bone marrow progenitor cells in patients with non-Hodgkin's lymphoma. , 1995, Blood.

[2]  J. Craig,et al.  Molecular detection of tumor contamination in peripheral blood stem cell harvests. , 1994, Experimental hematology.

[3]  J. Cornish,et al.  A laboratory comparison of T cell depletion by CD34+ cell immunoaffinity selection and in vitro Campath-1M treatment: clinical implications for bone marrow transplantation and donor leukocyte therapy , 1997, Bone Marrow Transplantation.

[4]  L. To,et al.  Identification and comparison of CD34-positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry. , 1991, Blood.

[5]  D. Wallwiener,et al.  Immunomagnetic selection of CD34+peripheral blood stem cells for autografting in patients with breast cancer , 1997, British journal of haematology.

[6]  I. Bernstein,et al.  Monoclonal antibody 12-8 recognizes a 115-kd molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors , 1986 .

[7]  A. Stewart,et al.  CD34 antigen: Molecular features and potential clinical applications , 1993, Stem cells.

[8]  R. Marcus,et al.  Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients , 1994, British journal of haematology.

[9]  R. Andrews,et al.  Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. , 1991, Blood.

[10]  F. Aversa,et al.  Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. , 1994, Blood.

[11]  J. Gribben,et al.  All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. , 1991, Blood.

[12]  N. Russell,et al.  STEM CELL MOBILIzATION IN NORMAL DONORS FOR ALLOGENEIC TRANSPLANTATION: ANALYSIS OF SAFETY AND FACTORS AFFECTING EFFICACY , 1996, British journal of haematology.

[13]  A. Lichtenstein,et al.  Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. , 1995, Blood.

[14]  A. Lichtenstein,et al.  The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. , 1994, Blood.

[15]  A. Hunter,et al.  Engraftment characteristics of peripheral blood stem cells mobilised with cyclophosphamide and the delayed addition of G-CSF. , 1995, Bone marrow transplantation.

[16]  N. Russell,et al.  Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate‐dose cyclophosphamide , 1997, British journal of haematology.

[17]  D. Linch,et al.  Evaluation of clinical scale CD34+ cell purification: experience of 71 immunoaffinity column procedures , 1997, Bone Marrow Transplantation.

[18]  B. Dupont,et al.  Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. , 1986, Blood.

[19]  D. Sutherland,et al.  The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. , 1996, Journal of hematotherapy.

[20]  R. Preti,et al.  Optimization of CD34+ cell selection using immunomagnetic beads: implications for use in cryopreserved peripheral blood stem cell collections. , 1997, Journal of hematotherapy.

[21]  J. Gribben,et al.  Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow , 1994 .

[22]  L. Kanz,et al.  Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors [see comments] , 1994 .

[23]  M. V. Veer,et al.  Translocation (14;18)-positive cells are present in the circulation of the majority of patients with localized (stage I and II) follicular non- Hodgkin's lymphoma , 1993 .

[24]  E. Shpall,et al.  Isolation of CD34-positive hematopoietic progenitor cells. , 1994, ImmunoMethods.

[25]  I McNiece,et al.  Large-scale isolation of CD34+ cells using the Amgen cell selection device results in high levels of purity and recovery. , 1997, Journal of hematotherapy.

[26]  R. Bataille,et al.  G‐CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myeloma and lymphoma , 1996, British journal of haematology.

[27]  L. Terstappen,et al.  Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. , 1995, Blood.